Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety

  • Ryan L. Crass
    Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA
  • Pier Giorgio Cojutti
    Department of Medicine, University of Udine, Udine, Italy
  • Manjunath P. Pai
    Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA
  • Federico Pea
    Department of Medicine, University of Udine, Udine, Italy

書誌事項

公開日
2019-08
権利情報
  • https://journals.asm.org/non-commercial-tdm-license
DOI
  • 10.1128/aac.00605-19
公開者
American Society for Microbiology

この論文をさがす

説明

<jats:p>Linezolid is administered as a fixed dose to all patients despite evidence of increased exposure and myelosuppression in renal impairment. The objectives of these studies were to assess the risk of thrombocytopenia with standard-dose linezolid in renal impairment and to identify an alternate dosing strategy.</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ